Evommune director sells shares, gets option grant

Evommune director David E. Cohen reported both stock sales and a new option grant.

Rhea-AI Filing Summary

Evommune director David E. Cohen reported both stock sales and a new option grant. He sold a total of 6,056 shares of common stock in two open-market transactions at weighted average prices of $20.21 and $21.38, executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026.

On the same date, he received a grant of stock options covering 15,673 shares of common stock with an exercise price of $19.82 per share, expiring on June 1, 2036. These options vest at the earlier of the first anniversary of the grant date or Evommune’s next annual meeting of stockholders, as long as he continues to serve through that date.

Insider Trade Summary 10b5-1

Net Seller: 6,056 shares

Net Sell 3 txns

Insider Cohen David E

Role Director

Sold 6,056 shs ($123K)

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	15,673	$0.00	$0.00
Sale	Common Stock	5,456	$20.21	$110K
Sale	Common Stock	600	$21.38	$13K

Holdings After Transaction: Stock Option (Right to buy) — 15,673 contracts (Direct); Common Stock — 17,609 shares (Direct)

Footnotes (4)

1. F1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.00 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.06 to $21.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
4. F4. The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Total shares sold: 6,056 shares Sale price (block 1): $20.21 per share Sale price (block 2): $21.38 per share +4 more

7 metrics

Total shares sold 6,056 shares Open-market sales of Evommune common stock on June 2, 2026

Sale price (block 1) $20.21 per share Weighted average price for 5,456 shares sold

Sale price (block 2) $21.38 per share Weighted average price for 600 shares sold

Option grant size 15,673 shares Stock option (right to buy) granted June 2, 2026

Option exercise price $19.82 per share Strike price for stock option grant

Option expiration June 1, 2036 Expiration date of Cohen’s Evommune stock options

Rule 10b5-1 plan adoption date March 3, 2026 Plan governing reported share sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to buy), annual meeting of stockholders

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to buy) financial

"security_title: Stock Option (Right to buy)"

annual meeting of stockholders regulatory

"shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Evommune (EVMN) director David E. Cohen report?

David E. Cohen reported selling 6,056 Evommune common shares and receiving a new stock option grant. The sales were open-market transactions, and the option grant gives him the right to buy 15,673 shares at a fixed exercise price.

How many Evommune (EVMN) shares did David E. Cohen sell and at what prices?

He sold 6,056 Evommune common shares in two open-market transactions. One block of 5,456 shares cleared at a weighted average of $20.21, and another 600 shares sold at a weighted average of $21.38 per share.

Was David E. Cohen’s Evommune (EVMN) share sale under a Rule 10b5-1 plan?

Yes. The filing states the transactions were executed under a Rule 10b5-1 trading plan adopted on March 3, 2026. Such plans are pre-arranged programs that schedule trades in advance, often used to make sales more routine and less timing-driven.

What are the terms of David E. Cohen’s new Evommune (EVMN) stock option grant?

He was granted options on 15,673 Evommune shares with a $19.82 exercise price, expiring on June 1, 2036. The options vest at the earlier of one year from grant or the next annual meeting, subject to his continued service.

How does the new Evommune (EVMN) option grant compare to David E. Cohen’s share sales?

Cohen sold 6,056 common shares but was granted options over 15,673 shares. The grant is a larger notional exposure than the shares sold, giving him potential future upside if Evommune’s stock trades above the $19.82 exercise price.

What does weighted average sale price mean in the Evommune (EVMN) Form 4?

The filing notes each sale price is a weighted average of multiple trades within a price range. For example, shares were sold between $20.00 and $20.99, with the reported number reflecting the average price across all individual executions in that range.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 08:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen David E

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		S(1)		5,456	D	$20.21(2)	18,209	D
Common Stock	06/02/2026		S(1)		600	D	$21.38(3)	17,609	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$19.82	06/02/2026		A		15,673		(4)	06/01/2036	Common Stock	15,673	$0.00	15,673	D

Explanation of Responses:

1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.

2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.00 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.06 to $21.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

4. The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)